---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-019321"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:12:01.651903+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio receives FDA alignment to advance XPro1595 to registrational study in Alzheimer's

## Summary
- FDA End-of-Phase 2 meeting yielded alignment to proceed with registrational study in biomarker-enriched early Alzheimer's patients.
- Phase 2 MINDFuL trial results and FDA feedback to be detailed in a webinar on Feb 27, 2026 at 9:30 AM ET.
- Company will seek a global partnership to maximize XPro1595's clinical and commercial potential.
- Key opinion leaders Dr. Michael Woodward and Dr. Sharon Cohen to present MINDFuL trial data and discuss pathway.

## SEC filing metadata
- accession: 0001213900-26-019321
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/0001213900-26-019321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/ea0277934-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-019321
- JSON: https://secwatch.observer/filing/0001213900-26-019321.json
- Plain text: https://secwatch.observer/filing/0001213900-26-019321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.